A comparative study on tumour response and treatment toxicities of two cycles versus three cycles of induction chemotherapy followed by concurrent chemoradiotherapy in the management of locoregional advanced head and neck cancer

Dorafiona Swer; Laishram Jaichand Singh; Yumkhaibam Sobita Devi; Ruby Panmei; Lakshmi Tirumala Gowtham Kilari; Mohan Babu B.

doi:10.18203/2320-6012.ijrms20252019

Authors

Dorafiona Swer Department of Radiation Oncology, Regional Institute of Medical Sciences, Imphal, Manipur, India https://orcid.org/0009-0006-1266-1844
Laishram Jaichand Singh Department of Radiation Oncology, Regional Institute of Medical Sciences, Imphal, Manipur, India
Yumkhaibam Sobita Devi Department of Radiation Oncology, Regional Institute of Medical Sciences, Imphal, Manipur, India
Ruby Panmei Department of Radiation Oncology, Regional Institute of Medical Sciences, Imphal, Manipur, India
Lakshmi Tirumala Gowtham Kilari Department of Radiation Oncology, Regional Institute of Medical Sciences, Imphal, Manipur, India
Mohan Babu B. Department of Radiation Oncology, Regional Institute of Medical Sciences, Imphal, Manipur, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20252019

Keywords:

Locally advanced head and neck cancer, Induction chemotherapy, induction chemotherapy

Abstract

Background: Locally advanced head and neck squamous cell carcinoma (LA-HNSCC) is being treated by multimodality approached, the rationale of using induction chemotherapy (ICT) is to shrink the tumors, enhance local control, and improved response, supporting the use of multiple ICT cycles. This study, compares two different courses of ICT followed by concurrent chemoradiotherapy to see the improvement in tumour response and treatment toxicities.

Methods: A randomized controlled trial conducted at the department of radiation oncology, RIMS, Imphal, from July 2022 to June 2024 after approval was obtained from institutional research ethics board (REB) with a total of 61 patients, where 31 patients recruited in arm-A and 30 patients in arm-B which compares two cycles versus three cycles of ICT followed by chemo-radiotherapy. Tumor response and toxicities were assessed using RTOG and RECIST criteria.

Results: Toxicities like oral mucositis, anemia, neutropenia, thrombocytopenia were seen more in arm B as compared to arm A and KFT toxicities were higher in arm A. Late toxicities like dermatitis, xerostomia, subcutaneous fibrosis were observed higher in arm-B. Partial response (PR) was observed better in arm B but progressive disease (PD) and stable disease (SD) were higher in arm A.

Conclusions: Arm B showed slightly better tumor shrinkage but had more side effects with mucositis, nausea, and blood-related issues. Late toxicities were slightly higher in arm B. However, these differences were not statistically significant. Overall, both arms showed similar effectiveness. More research is needed to find the ideal number of ICT cycles that maximize response and minimize side effects.

Metrics

Metrics Loading ...

References

Semple CJ, Sullivan S, Dunwoody L, Kernohan WG. Psychosocial interventions for patients with head and neck cancer. Cancer Nursing. 2004;27(6):434-40. DOI: https://doi.org/10.1097/00002820-200411000-00002

Sung H, Ferlay J, Siegel R L, Mathieu L, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49. DOI: https://doi.org/10.3322/caac.21660

Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020;6(1):92. DOI: https://doi.org/10.1038/s41572-020-00224-3

Bray F, Ferlay J, Soerjomataram I, Rebecca L. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2018;68(6):394-424. DOI: https://doi.org/10.3322/caac.21492

Hashibe M, Brennan P, Chuang S-C, Stefania B, Xavier C, Chu C, et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev. 2009;18(2):541-50.

Mendenhall WM, Werning JW, Pfister DG. Cancer of the head and neck. In: DeVita VT, Hellman S, Rosenberg SA, 10th ed. Cancer: Principals and practice of Oncology. Philadelphia: Wolters Kluwer. 2015;422-4.

Gandhi AK, Roy S, Thakar A, Sharma A, Mohanti BK. Symptom burden and quality of life in advanced head and neck cancer patients: AIIMS study of 100 patients. Indian J Palliat Care. 2014;20(3):189-93. DOI: https://doi.org/10.4103/0973-1075.138389

Agarwal JP, Nemade B, Murthy V, Laskar SG, Budrukkar A, Gupta T, et al. Hypofractionated, palliative radiotherapy for advanced head and neck cancer. Radiother Oncol. 2008;89(1):51-6. DOI: https://doi.org/10.1016/j.radonc.2008.06.007

Mukherji SK, Armao D, Joshi VM. Cervical nodal metastases in squamous cell carcinoma of the head and neck: what to expect. Head Neck. 2001;23(11):995-1005. DOI: https://doi.org/10.1002/hed.1144

Wolf TG, Hong WK, Fisher SG, Urba S, Endicott JW, Close L, et al. The department of veterans’ affairs laryngeal cancer study group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324(24):1685-90. DOI: https://doi.org/10.1056/NEJM199106133242402

Hong WK and Biomer R. Current concepts: Chemotherapy in Head and Neck Cancer. N. Engl J Med. 1983;308(2):75-8. DOI: https://doi.org/10.1056/NEJM198301133080204

Bhide SA, Ahmed M, Barbachano Y, Newbold K, Harrington KJ, Nutting CM. Sequential induction chemotherapy followed by radical chemo-radiation in the treatment of locoregionally advanced head- and- neck cancer. Br J Cancer. 2008;99(1):57-62.

Goel A, Singla A, Prabhash K. Neoadjuvant chemotherapy in oral cancer: Current status and future possibilities. Cancer Res Stat Treat. 2020;3:51-9. DOI: https://doi.org/10.4103/CRST.CRST_79_19

Radiation Therapy Oncology Group. RTOG acute and late Radiation Morbidity Scoring criteria. Available at: http://www.rtog.org/ResearchAssociates/Adverse Event Reporting/Acute and late Radiation Morbidity Scoring Criteria.aspx. Accessed on 10 April 2025.

Eisenhauer A, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1). European J of Cancer. 2009;45(2):228-47. DOI: https://doi.org/10.1016/j.ejca.2008.10.026

Michaelraj MJ, Kuttiappan K, Ramasamy S, Rodrigues FAE, Govindaraj S. Demographic profile and risk factors of head-and-neck squamous cell carcinoma in west Tamil Nadu: A cross-sectional observational study. Cancer Res Stat Treat. 2023;6(2):215-223. DOI: https://doi.org/10.4103/crst.crst_364_22

Sanghera P, McConkey C, Ho KF, Glaholm J, Hartley A. Hypofractionated accelerated radiotherapy with concurrent chemotherapy for locally advanced squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2007;67(5):1342-51. DOI: https://doi.org/10.1016/j.ijrobp.2006.11.015

Hashibe M, Brennan P, Chuang SC, Boccia S, Castellsague X, Chen C, et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev. 2009;18(2):541-50. DOI: https://doi.org/10.1158/1055-9965.EPI-08-0347

Gupta T, Agarwal JP, Ghosh-Laskar S, Parikh PM, D'Cruz AK, Dinshaw KA. Radical radiotherapy with concurrent weekly cisplatin in loco-regionally advanced squamous cell carcinoma of the head and neck: a single-institution experience. Head Neck Oncol. 2009;1:17. DOI: https://doi.org/10.1186/1758-3284-1-17

Mathur P, Kumar SK, Chaturvedi M, Das P, Sudarshan KL, Santhappan S, et al. Cancer Statistics, 2020: Report from National Cancer Registry Programme, India. JCO Glob Oncol. 2020;6:1063-75. DOI: https://doi.org/10.1200/GO.20.00122

Laursen M, Specht L, Kristensen CA, Gothelf A, Bernsdorf M, Vogelius I, et al. An Extended Hypofractionated Palliative Radiotherapy Regimen for Head and Neck Carcinomas. Front Oncol. 2018;8(1):206. DOI: https://doi.org/10.3389/fonc.2018.00206

Porceddu SV, Rosser B, Burmeister BH, Jonesc M, Hickeya B, Baumannd K, et al. Hypofractionated radiotherapy for the palliation of advanced head and neck cancer in patients unsuitable for curative treatment-hypo trial. Radiother Oncol. 2007;85(3):456-62. DOI: https://doi.org/10.1016/j.radonc.2007.10.020

Paccagnella A, Ghi MG, Loreggian L, Buffoli A, Koussis H, Mione CA, et al. Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study. Ann Oncol. 2010;21(7):1515-22. DOI: https://doi.org/10.1093/annonc/mdp573

Bhide SA, Ahmed M, Barbachano Y, Newbold K, Harrington KJ, Nutting CM. Sequential induction chemotherapy followed by radical chemo-radiation in the treatment of locoregionally advanced head- and- neck cancer. Br J Cancer. 2008;99(1):57-62. DOI: https://doi.org/10.1038/sj.bjc.6604444

Hitt R, Lo´pez-Pousa A, Martínez-Trufero J, Escrig V, Carles J, Rizo A, et al. Phase III study Comparing Cisplatin Plus Fluorouracil to Paclitaxel, Cisplatin, and Fluorouracil Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced Head and Neck Cancer. J Clin Oncol. 2005;23(34):8636-45. DOI: https://doi.org/10.1200/JCO.2004.00.1990

Somani N, Goyal S, Pasricha R, Khuteta N, Agarwal P, Garg AK, et al. Sequential therapy (triple drug-based induction chemotherapy followed by concurrent chemoradiotherapy) in locally advanced inoperable head and neck cancer patients - Single institute experience. Indian J Med Paediatr Oncol. 2011;32:86-91. DOI: https://doi.org/10.4103/0971-5851.89781

Gnanaguru V, Dhanushkodi M, Radhakrishnan V, Kalaiarasi JP, Rajan AK, Selvarajan G, et al. Induction chemotherapy in locally advanced head-and-neck squamous cell carcinoma: Real-world outcome. Oncol J India. 2020;4:105-9. DOI: https://doi.org/10.4103/oji.oji_21_20

Joshi P, et al. Neo-adjuvant chemotherapy in advanced hypopharyngeal carcinoma. J Oncol. 2019;10(2):123-35.